10-K: Dexcom Reports Strong 2025 Growth, New CGM Systems Drive Revenue

Dexcom, Inc. announced robust financial results for fiscal year 2025, driven by increased sales volume of its continuous glucose monitoring systems and the launch of new products like G7 15 Day and Stelo.

Summary

• Revenue increased by 16% to $4.66 billion in 2025, up from $4.03 billion in 2024.
• Net income grew by 45% to $836.3 million in 2025, compared to $576.2 million in 2024.
• Operating income surged by 52% to $911.8 million in 2025, from $600.0 million in 2024.
• Operating cash flow increased by 46% to $1.44 billion in 2025, up from $989.5 million in 2024.
• The company added approximately 600,000 700,000 net customers to its worldwide base in 2025, excluding Stelo customers.
• Launched the Dexcom G7 15 Day Continuous Glucose Monitoring System in late 2025, extending the wear period to 15.5 days.
• Launched Stelo in August 2024, as the first over-the-counter glucose biosensor in the U.S., targeting adults with prediabetes and Type 2 diabetes who do not use insulin.
• Repurchased 7.7 million shares of common stock for $500.0 million under the 2025 Share Repurchase Program as of December 31, 2025.
• Repaid $1.21 billion principal amount of 0.25% unsecured senior convertible notes due 2025 upon maturity in November 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report, reflecting robust financial growth, successful product launches, and significant customer expansion. While regulatory and competitive pressures exist, the company's innovation and market penetration indicate a positive trajectory.

Positives

• Achieved strong financial growth in 2025 with revenue up 16%, gross profit up 15%, operating income up 52%, net income up 45%, and operating cash flow up 46%.
• Expanded its worldwide customer base by approximately 600,000 700,000 net customers (excluding Stelo) in 2025.
• Successfully launched the Dexcom G7 15 Day system, offering extended wear and high accuracy (8.0% MARD), making it the most accurate CGM cleared by the FDA.
• Introduced Stelo in August 2024, the first over-the-counter glucose biosensor in the U.S., expanding market access to prediabetes and non-insulin Type 2 diabetes populations.
• Maintained effective internal control over financial reporting as of December 31, 2025, as audited by Deloitte & Touche LLP.
• Received a tax benefit related to the commencement of a Malaysia tax holiday, retroactively applied to January 1, 2024.

Negatives

• Gross profit margin percentage decreased in 2025 compared to 2024, primarily due to inefficiencies in ensuring supply availability, build configurations that lowered production yield, and total replacement costs.
• Experienced pricing headwinds due to greater rebate eligibility and channel mix.
• Medicare reimbursement for CGM systems is expected to decrease beginning in 2028 due to changes in the Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) competitive bidding program.
• Interest and dividend income decreased by $21.5 million in 2025 compared to 2024, attributed to changes in market interest rates and a decrease in average invested balances.
• Research and development expenses increased by $46.7 million, and selling, general and administrative expenses increased by $5.2 million, primarily due to higher compensation and related costs.
• Received an FDA warning letter in March 2025 citing deficiencies in manufacturing processes and the quality management system at its San Diego and Mesa facilities.
• Subject to multiple ongoing legal proceedings, including securities class actions, derivative actions, and G6/G7 product liability class actions, which could incur significant costs and divert management attention.

Risks

• Decreasing product prices and inability to reduce expenses, including per-unit production costs, could materially adversely affect business, results of operations, financial condition, and cash flows.
• Inability to obtain adequately broad coverage or reimbursement for products from third-party payors could negatively impact revenue.
• Research and development efforts may not result in commercially viable products, significant future revenues, or adequate profitability.
• Products may not achieve or maintain market acceptance, especially with increasing competition from large, well-established companies and new market entrants, including those in the general health and wellness space.
• Failure to comply with ongoing regulatory requirements, including responding to the FDA warning letter, or unanticipated product problems, could lead to product restrictions or market withdrawal.
• Insufficient manufacturing capabilities or disruptions at facilities could limit growth and harm the business.
• Dependence on third-party suppliers and outsourcing makes the company vulnerable to supply disruptions, suboptimal quality, non-compliance, and price fluctuations.
• Inability to establish and maintain adequate sales, marketing, and distribution capabilities, or to secure third-party arrangements, could hinder market awareness and product sales.
• International operations expose the company to risks such as local product preferences, foreign currency fluctuations, less intellectual property protection, trade protection measures, workforce instability, and political/economic instability.
• Subject to complex and evolving U.S. and international laws and regulations regarding privacy, data protection, and security, which could result in claims, monetary penalties, increased operational costs, or declines in user engagement.
• Cybersecurity risks and incidents could compromise confidential data or critical systems, leading to harm to customers, remediation expenses, liability under HIPAA, litigation, and reputational damage.
• Failure to comply with applicable laws and government regulations in a heavily regulated industry could result in penalties, exclusion from government programs, or significant operational changes.
• Managed care trends and consolidation in the healthcare industry could adversely affect revenues and results of operations.
• Inability to successfully complete pre-clinical studies or clinical trials necessary for additional regulatory applications could impair commercialization of CGM systems under development.
• Healthcare policy changes, including U.S. health care reform legislation like the 'One Big Beautiful Bill Act' impacting Medicaid and ACA enrollment, may have a material adverse effect on the business.
• Claims of infringement or misappropriation of intellectual property rights of others could prohibit product shipments, require licenses, or lead to substantial monetary damages and injunctive relief.
• Inability to adequately protect intellectual property could allow competitors to produce products based on the company's technology, substantially impairing its ability to compete.
• Risk of product liability claims, potentially leading to damages, fines, penalties, and injunctions.
• Could become the subject of governmental investigations, claims, and litigation.
• Has incurred significant losses in the past and may incur losses in the future.
• Stock price is highly volatile, and investing in the stock involves a high degree of risk.
• Indebtedness in the form of convertible senior notes could adversely affect financial health and ability to respond to business changes.
• Sustainability (including environmental, social, and governance) regulations, policies, and provisions could expose the company to numerous risks.
• Climate change may have an adverse impact on the business, including disruptions to manufacturing sites and supply chains.
• May be adversely affected by the effects of inflation, increasing overall cost structure.
• Failure to successfully maintain effective internal control over financial reporting could adversely impact investor confidence and stock price.
• Changes in financial accounting standards or practices or existing taxation rules or practices may cause adverse unexpected revenue and/or expense fluctuations and affect reported results of operations.

Future Outlook

Dexcom plans to continue developing future generations of technologies focused on improved performance, convenience, and intelligent insulin administration, including networked platforms with open architecture and enhanced connectivity. The company intends to expand its efforts in accumulating CGM patient data and applying predictive modeling and machine learning to generate interactive insights. Strategic partnerships with insulin pump companies, automated insulin delivery systems, and consumer technology product companies (for Stelo) will be pursued and supported. Dexcom is also exploring new market opportunities for people with pre-diabetes, obese individuals, pregnant people, and in hospital settings, with potential expansion beyond glucose monitoring in the longer term. The company anticipates transitioning G6 customers to G7 and G7 15 Day systems by the end of 2026 and phasing out the previous generation Dexcom ONE system by the same time. However, Medicare reimbursement for CGM systems is expected to decrease starting in 2028 due to competitive bidding program changes.

Management Comments

• Management believes that focused investments in research and development are critical to future growth and competitive position, and to the development of new and updated products and services central to the core business strategy.
• The company takes the matters identified in the FDA warning letter seriously and has submitted responses to the Form 483 and to the FDA warning letter.
• Existing cash and short-term investments and cash flows from future operations are expected to be generally sufficient to fund ongoing core business.

Industry Context

StockSavvy.ai notes that Dexcom's strong revenue growth and customer acquisition in 2025 demonstrate continued leadership in the rapidly expanding continuous glucose monitoring market. The launch of G7 15 Day and the over-the-counter Stelo biosensor positions Dexcom to capture broader segments, including non-insulin users and those focused on metabolic health, aligning with a broader industry trend towards preventative and personalized health management. However, the anticipated decrease in Medicare reimbursement from 2028 due to competitive bidding, coupled with increasing competition from established players like Abbott and Medtronic, and emerging general wellness device companies, highlights the evolving pricing and market access challenges in the medical device sector. The increasing use of GLP-1 products for diabetes and obesity also presents a dynamic competitive landscape, requiring Dexcom to continuously innovate and differentiate its offerings.

Comparison to Industry Standards

• The Dexcom G7 15 Day system boasts a Mean Absolute Relative Difference (MARD) of 8.0% and 94.2% of values within 20% of their comparator, making it the most accurate CGM cleared by the FDA. This positions it favorably against competitors like Abbott's Libre family and Medtronic's Guardian Connect and Simplera.
• The G7's 30-minute sensor warm-up is highlighted as the fastest of any CGM on the market, offering a significant convenience advantage over existing and emerging competitive devices.
• Dexcom's strategy to integrate its CGM technology with insulin pumps, smart insulin pens, Apple Watch, Garmin, and other digital health apps aligns with the broader industry trend of creating a connected CGM ecosystem, similar to Abbott Diabetes Care's efforts to integrate Libre sensors into automated insulin delivery systems.
• The launch of Stelo as an over-the-counter biosensor for prediabetes and non-insulin Type 2 diabetes directly addresses the growing 'general health and wellness, or population health space,' where companies outside the traditional medical device sector are developing competitive products, as noted in recent FDA guidance.

Management Changes

Corporate Governance

Legal Proceedings

• Three substantially similar putative securities class action complaints were filed between August 21 and October 9, 2024, consolidated as 'In re Dexcom, Inc. Class Action Securities Litigation,' alleging violations of the Exchange Act for false and misleading statements regarding expected 2024 revenue and growth potential between April 28, 2023, and July 25, 2024. The court granted a motion to dismiss with leave to amend on May 14, 2025, and a subsequent motion for judgment on the pleadings with leave to amend on January 7, 2026. A second amended consolidated complaint was filed on February 6, 2026.
• Another putative securities class action complaint, 'Prime v. Dexcom, Inc., et al,' was filed on October 27, 2025, alleging Exchange Act violations for false and misleading statements between July 26, 2024, and September 17, 2025, concerning the accuracy, reliability, functionality, enhancements, and manufacturing of the G7 device. An amended complaint is due by April 10, 2026.
• Three putative stockholder derivative lawsuits were filed between September 13 and April 14, 2025, consolidated as 'In Re: Dexcom, Inc. Stockholder Derivative Litigation,' largely tracking the allegations of the securities class action and seeking damages and restitution from individual defendants. These actions are currently stayed.
• An additional derivative lawsuit was filed on September 25, 2025, in the Court of Chancery of the State of Delaware, with similar allegations, and is also currently stayed.
• Six overlapping putative class action complaints were filed between September 29, 2025, and January 8, 2026, by purported users of G6 or G7 devices, alleging overpayment for adulterated/misbranded devices, failure to perform as advertised, and misleading statements about safety, accuracy, efficacy, and reliability. These actions assert various state law consumer protection, warranty, and common law claims, seeking damages, restitution, disgorgement, and injunctive relief. The federal cases have been deemed related and are stayed pending a consolidated complaint, while a state court case is also stayed.

Stakeholder Impact

• **Shareholders**: Potential for increased value from strong financial performance and share repurchase programs, but also face risks from stock price volatility, potential dilution from convertible notes, and the costs/outcomes of ongoing legal proceedings. No dividends are expected in the foreseeable future.
• **Employees**: Benefit from competitive total rewards, pay equity reviews, and investment in talent growth and development. The company's hybrid work model supports work-life balance. However, workforce reorganizations could lead to temporary reductions in employee numbers.
• **Customers (Patients, Caregivers, Clinicians)**: Gain access to advanced, more accurate, and convenient CGM systems like G7 15 Day and the over-the-counter Stelo, potentially leading to improved health outcomes. However, anticipated decreases in Medicare reimbursement from 2028 could impact affordability and access for some beneficiaries. Product liability claims and regulatory issues could also affect product availability or trust.
• **Suppliers**: The company's dependence on single and sole-source suppliers for critical components creates a risk of supply disruptions, quality issues, and price fluctuations, which could impact supplier relationships and the company's ability to meet demand.
• **Creditors**: The company's indebtedness from convertible senior notes and its credit facility affects its financial health and ability to respond to business changes. Compliance with debt covenants is crucial to avoid defaults.

Next Steps

• Transition G6 customers to G7 and G7 15 Day sensor systems by the end of 2026.
• Phase out the previous generation Dexcom ONE CGM system by the end of 2026.
• Continue to develop future generations of technologies focused on improved performance, convenience, and intelligent insulin administration.
• Expand efforts to accumulate CGM patient data and apply predictive modeling and machine learning to generate interactive CGM insights.
• Pursue and support development partnerships with insulin pump companies, automated insulin delivery systems, and consumer technology product companies (for metabolic health insights).
• Explore extending product offerings to people with pre-diabetes, obese individuals, pregnant people, and in the hospital setting.
• Undertake corrective actions and provide regular updates to the FDA to resolve matters included in the March 2025 warning letter.
• Prepare for the DMEPOS competitive bidding program for CGMs, with contracting beginning in 2027 and payment changes effective January 1, 2028.
• Monitor and adapt to evolving sustainability regulations, policies, and stakeholder expectations, including new EU and California reporting requirements.

Key Dates

Recommendation

Dexcom's 2025 financial performance, marked by double-digit revenue and profit growth, along with successful product launches like G7 15 Day and Stelo, demonstrates strong operational execution and market expansion. The company's commitment to innovation in CGM technology and broadening access to metabolic health solutions is commendable. However, the FDA warning letter, the anticipated reduction in Medicare reimbursement from 2028, and a highly competitive landscape, including the rise of GLP-1 drugs and general wellness devices, present material headwinds. The ongoing securities and product liability class action lawsuits also introduce significant legal and reputational risks. While the long-term growth trajectory for CGM remains positive, these challenges suggest a period of increased uncertainty and potential margin pressure. A 'hold' recommendation reflects the balance between strong underlying business fundamentals and significant, evolving risks that could impact future profitability and stock performance.

Keywords

Continuous Glucose Monitoring (CGM), Diabetes Management, Medical Devices, Dexcom G7, Stelo, Healthcare Technology, Financial Performance, Regulatory Compliance, Product Development, Market Acceptance, Cybersecurity, Intellectual Property, Share Repurchase, Convertible Notes, FDA Warning Letter, Medicare Reimbursement